Endo International Plc - Company Profile
Powered by 
All the data and insights you need on Endo International Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Endo International Plc Strategy Report
- Understand Endo International Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Endo International Plc (Endo) focuses on the research, development, and marketing of various branded and generic pharmaceuticals, besides OTC products in the area of pain management, oncology, urology, pelvic health and endocrinology. The company operates through its three operating companies: Endo Pharmaceuticals, Par Pharmaceutical and Paladin Labs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
The company’s R&D efforts are focused on the development of a balanced and diversified portfolio of clinically differentiated products. The company conducts its research and development activities in two major areas: Specialty pharmaceutical and medical therapeutics; and sterile injectables and high value generics medicines. It has research and development programmes in men’s health, orthopedics and endocrinology therapeutic areas. The company's core team development model provides a platform for individuals with different skill sets to connect and share ideas, which drives the innovation process of the company. As a result of this collaboration, the company has identified the role of collagenase in the treatment of several collagen fiber disorders. Endo also focuses on developing generic pharmaceutical products for therapeutic categories such as antihypertensives, analgesics, antibiotics, antidepressants, and antipsychotics. In FY2022, the company spent US$128.03 million on its R&D activities, which as a percentage of its revenue, stood at 10.4% and increased 3.7% YoY. As of February 2023, the company held 154 US issued patents, 427 foreign issued patents, 45 US patent applications pending and 119 foreign patent applications pending. The company also holds licenses for 73 US issued patents, 167 foreign issued patents, 14 US patent applications pending and 83 foreign patent applications pending.
Business Segments
Overview
It includes branded prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics areas. Major products include Xiaflex, Supprelin LA, Nascobal Nasal Spray, Testopel, Aveed, Percocet, Voltaren Gel, Lidoderm, Fortesta Gel, Edex and Testim. It intends to accelerate the performance of organic growth drivers in its specialty products portfolio and expanding margin in its established products portfolio.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
The segment operates through Par Pharmaceutical. It develops, manufactures and markets generic pharmaceutical products in the areas of urology, pain management, CNS disorders, Cancer, immunosuppression, women’s health and cardiovascular disease markets, among others. Its products include liquids, semi-solids, patches, powders, solid oral extended-release, solid oral immediate-release, ophthalmics and sprays. Envisages developing or acquiring high-barrier-to-entry products, including first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. Also focuses on acquisition and integration to expand its existing generics platform.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers a variety of specialty pharmaceutical products in Canada, Mexico, South Africa and certain other non-US markets. The segment operates through Paladin Labs, which focuses on therapeutic areas including ADHD, pain, women’s health and oncology.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Consists of branded sterile injectable products and certain generic sterile injectable products, including, ertapenem for injection and ephedrine sulfate injection. Major products include Vasostrict, Adrenalin and Aplisol, The company manufactures these injectable products in a sterile facility and sells them through wholesalers. Focuses on the development of branded injectable products and expanding the product portfolio to include other dosages and technologies that are difficult to manufacture.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer